CO6341631A2 - Derivados de 1,2,4 - oxadiazol y su uso terapéutico - Google Patents
Derivados de 1,2,4 - oxadiazol y su uso terapéuticoInfo
- Publication number
- CO6341631A2 CO6341631A2 CO11075839A CO11075839A CO6341631A2 CO 6341631 A2 CO6341631 A2 CO 6341631A2 CO 11075839 A CO11075839 A CO 11075839A CO 11075839 A CO11075839 A CO 11075839A CO 6341631 A2 CO6341631 A2 CO 6341631A2
- Authority
- CO
- Colombia
- Prior art keywords
- group
- groups
- alkyl
- aminoalkyl
- hydrogen atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Nuevos derivados de fórmula general (I), o sales farmacéuticamente aceptables o N-óxidos de los mismos, donde,(i) A se selecciona del grupo que consiste en -N-, -O- y -S-; B y C se seleccionan independientemente del grupo que consiste en -N- y -O-, con a condición de que al menos dos de A, B y C sean átomos de nitrógeno; o (ii) dos de A, B y C; son -N- y uno de A, B y C es-NH-;G1 se selecciona del grupo que consiste en -CH2-, -NH- y -O-;G2 se seleccione del grupo que consiste en -NR4- y -O-;R1 representa:> un grupo heteroarilo que contiene N, biciclico, de 8 a 10 miembros, opcionalmente sustituido con un grupo carboxialquilo C1-4 o un grupo aminoalquilo C1-4,> un grupo piridilo opcionalmente sustituido con uno o más sustituyentes seleccionados de grupos hidroxi, grupos alquilo C1-4, grupos carboxialquilo C1-4, grupos haloalquilo C1-4, grupos alcoxi C1-4, grupos amino, grupos aminoalquilo C1-4 y grupos aminoalcoxi C1-4,> un grupo piridona sustituido con uno o más grupos alquilo C1-4; grupos haloalquilo C1-4, o grupos aminoalquilo C1-4, oun grupo de fórmula:donde:° Ra representa un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C1-4, un grupo cicloalquilo C1-4 o un grupo -CF3;° Rb representa un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C1-4, un grupo -CF3 o un grupo alcoxi C1-4;° Rd representa un átomo de hidrógeno, un grupo alquilo C1-4 o un grupo alcoxi C1-4; ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08382090A EP2202232A1 (en) | 2008-12-26 | 2008-12-26 | 1,2,4-oxadiazole derivatives and their therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6341631A2 true CO6341631A2 (es) | 2011-11-21 |
Family
ID=40671021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11075839A CO6341631A2 (es) | 2008-12-26 | 2011-06-17 | Derivados de 1,2,4 - oxadiazol y su uso terapéutico |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20110311485A1 (es) |
| EP (2) | EP2202232A1 (es) |
| JP (1) | JP2012513958A (es) |
| KR (1) | KR20110104075A (es) |
| CN (1) | CN102264731A (es) |
| AR (1) | AR074902A1 (es) |
| AU (1) | AU2009331959A1 (es) |
| BR (1) | BRPI0918194A2 (es) |
| CA (1) | CA2748397A1 (es) |
| CO (1) | CO6341631A2 (es) |
| EA (1) | EA201100975A1 (es) |
| EC (1) | ECSP11011083A (es) |
| IL (1) | IL213168A0 (es) |
| MX (1) | MX2011006505A (es) |
| SG (1) | SG172152A1 (es) |
| TW (1) | TW201024287A (es) |
| UY (1) | UY32296A (es) |
| WO (1) | WO2010072352A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| EP2366702A1 (en) * | 2010-03-18 | 2011-09-21 | Almirall, S.A. | New oxadiazole derivatives |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| BR112012028652A2 (pt) | 2010-05-08 | 2016-08-09 | Bayer Ip Gmbh | hidroxialquilbenzilpirazois e seu uso |
| JP5727002B2 (ja) | 2010-05-08 | 2015-06-03 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換ヘテロサイクリルベンジルピラゾール類およびその使用 |
| ES2539256T3 (es) * | 2010-07-20 | 2015-06-29 | Bristol-Myers Squibb Company | Compuestos de 3-fenil-1,2,4-oxadiazol sustituidos |
| CN103298807A (zh) * | 2010-11-03 | 2013-09-11 | 百时美施贵宝公司 | 作为用于治疗自身免疫性疾病和血管疾病的s1p1激动剂的杂环化合物 |
| EP2455080A1 (en) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
| EP2455081A1 (en) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of crohn's disease |
| KR101299512B1 (ko) * | 2011-04-19 | 2013-08-22 | 전북대학교산학협력단 | 스핑고신 1-포스페이트를 유효성분으로 함유하는 관절염 질환 치료 조성물 |
| WO2013025984A2 (en) * | 2011-08-18 | 2013-02-21 | Temple University | Cannabinoid receptor treatments |
| CN104254533B (zh) * | 2012-01-13 | 2017-09-08 | 百时美施贵宝公司 | 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物 |
| CA2876215A1 (en) | 2012-07-02 | 2014-01-09 | Monsanto Technology Llc | Processes for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles |
| HUE039931T2 (hu) | 2013-02-20 | 2019-02-28 | Lg Chemical Ltd | Szfingozin-1-foszfát receptor agonisták, azok elkészítési eljárásai, és azokat aktív ágensként tartalmazó gyógyszerészeti készítmények |
| UY35338A (es) | 2013-02-21 | 2014-08-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen |
| TW201534586A (zh) | 2013-06-11 | 2015-09-16 | Orion Corp | 新穎ｃｙｐ１７抑制劑／抗雄激素劑 |
| AR101591A1 (es) | 2014-08-20 | 2016-12-28 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos |
| MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| CN110461838B (zh) * | 2017-03-07 | 2022-05-06 | 豪夫迈·罗氏有限公司 | 噁二唑瞬时受体电位通道抑制剂 |
| WO2018187479A1 (en) | 2017-04-04 | 2018-10-11 | Case Western Reserve University | Method of modulating ribonucleotide reductase |
| CN108546266B (zh) * | 2018-07-25 | 2020-09-22 | 上海毕得医药科技有限公司 | 一种1,4,6,7-四氢吡喃[4,3-c]吡唑-3-羧酸的合成方法 |
| EP4077316A1 (en) | 2019-12-20 | 2022-10-26 | Pfizer Inc. | Benzimidazole derivatives |
| CA3236553A1 (en) | 2021-10-29 | 2023-05-04 | Joel Worley BEATTY | Inhibitors of hif-2alpha and methods of use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2303792A (en) | 1992-06-23 | 1994-01-24 | Motorola, Inc. | Multi-modulation scheme compatible radio |
| EP0837710B1 (en) | 1995-06-21 | 2001-11-28 | ASTA Medica Aktiengesellschaft | Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments |
| IL158324A0 (en) * | 2001-04-19 | 2004-05-12 | Bayer Ag | Arylsulphonamides as anttiviral agents |
| DE10129703A1 (de) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
| DE10202940A1 (de) | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
| SI1505959T1 (sl) | 2002-05-16 | 2009-04-30 | Novartis Ag | Uporaba vezavnih sredstev EDG receptorjev pri raku |
| GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
| EP1484057A1 (en) | 2003-06-06 | 2004-12-08 | Aventis Pharma Deutschland GmbH | Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain |
| JP4861177B2 (ja) | 2003-09-12 | 2012-01-25 | ニューロノバ エービー | 神経系の障害の処置 |
| GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
| KR20080086546A (ko) | 2006-01-27 | 2008-09-25 | 유니버시티 오브 버지니아 페이턴트 파운데이션 | 신경병증성 통증의 치료 방법 |
| TWI389683B (zh) | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| PL2003132T3 (pl) * | 2006-04-03 | 2014-10-31 | Astellas Pharma Inc | Pochodne oksadiazolu jako agoniści S1P1 |
| ES2414205T3 (es) | 2006-06-02 | 2013-07-18 | The Ohio State University Research Foundation | Agentes terapéuticos para el tratamiento de linfoma de células del manto |
| GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
| AU2007284337B2 (en) | 2006-08-17 | 2012-07-19 | University Of Chicago | Treatment of inflammatory diseases |
| JO2701B1 (en) * | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
-
2008
- 2008-12-26 EP EP08382090A patent/EP2202232A1/en not_active Withdrawn
-
2009
- 2009-12-04 UY UY0001032296A patent/UY32296A/es not_active Application Discontinuation
- 2009-12-14 TW TW098142730A patent/TW201024287A/zh unknown
- 2009-12-15 CN CN2009801528657A patent/CN102264731A/zh active Pending
- 2009-12-15 AU AU2009331959A patent/AU2009331959A1/en not_active Abandoned
- 2009-12-15 JP JP2011542702A patent/JP2012513958A/ja active Pending
- 2009-12-15 MX MX2011006505A patent/MX2011006505A/es not_active Application Discontinuation
- 2009-12-15 BR BRPI0918194A patent/BRPI0918194A2/pt not_active Application Discontinuation
- 2009-12-15 US US13/142,104 patent/US20110311485A1/en not_active Abandoned
- 2009-12-15 EP EP09771316A patent/EP2370431A1/en not_active Withdrawn
- 2009-12-15 SG SG2011043510A patent/SG172152A1/en unknown
- 2009-12-15 CA CA2748397A patent/CA2748397A1/en not_active Abandoned
- 2009-12-15 KR KR1020117017302A patent/KR20110104075A/ko not_active Application Discontinuation
- 2009-12-15 EA EA201100975A patent/EA201100975A1/ru unknown
- 2009-12-15 WO PCT/EP2009/008968 patent/WO2010072352A1/en active Application Filing
- 2009-12-23 AR ARP090105087A patent/AR074902A1/es unknown
-
2011
- 2011-05-25 EC EC2011011083A patent/ECSP11011083A/es unknown
- 2011-05-26 IL IL213168A patent/IL213168A0/en unknown
- 2011-06-17 CO CO11075839A patent/CO6341631A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2370431A1 (en) | 2011-10-05 |
| TW201024287A (en) | 2010-07-01 |
| CN102264731A (zh) | 2011-11-30 |
| BRPI0918194A2 (pt) | 2015-12-01 |
| KR20110104075A (ko) | 2011-09-21 |
| JP2012513958A (ja) | 2012-06-21 |
| AR074902A1 (es) | 2011-02-23 |
| SG172152A1 (en) | 2011-07-28 |
| US20110311485A1 (en) | 2011-12-22 |
| EA201100975A1 (ru) | 2012-02-28 |
| IL213168A0 (en) | 2011-07-31 |
| WO2010072352A1 (en) | 2010-07-01 |
| UY32296A (es) | 2010-05-31 |
| ECSP11011083A (es) | 2011-06-30 |
| MX2011006505A (es) | 2011-07-12 |
| CA2748397A1 (en) | 2010-07-01 |
| EP2202232A1 (en) | 2010-06-30 |
| AU2009331959A1 (en) | 2011-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6341631A2 (es) | Derivados de 1,2,4 - oxadiazol y su uso terapéutico | |
| NO20060670L (no) | N3-substituerte imidazopyridin C-kit inhibitorer | |
| UA95976C2 (en) | 2-ARYL-6-PHENYLIMIDAZO[1,2-b]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | |
| MX2013004407A (es) | Derivado de piridina y agente medicinal. | |
| NO20060664L (no) | N-substituerte benzimidazolyl C-kit inhibitorer | |
| MY149853A (en) | Pyridin-4-yl derivatives as immunomodulating agents | |
| GEP20156267B (en) | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | |
| NO20060665L (no) | N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer | |
| TW200738655A (en) | Novel bicyclic sulfonamide derivatives | |
| BRPI0718966B8 (pt) | composto, composição farmacêutica, inibidor plk1 e agente antitumoral | |
| TW200833324A (en) | Sulfonamide derivatives | |
| ATE553106T1 (de) | Heteroarylpyrrolopyridinone als kinaseinhibitoren | |
| AR089568A1 (es) | Compuestos heterociclicos y sus metodos de usos | |
| UY31712A1 (es) | Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmacéuticas que los contienen | |
| EA201170093A1 (ru) | Замещенные n-оксидпиразиновые производные | |
| CO6321168A2 (es) | Nuevos derivados de 2-amidotiadiazol | |
| NO20080033L (no) | Kinolinderivater som NK3-antagonister | |
| MY183039A (en) | Pyridin-2-yl derivatives as immunomodulating agents | |
| NI201000134A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| AR089297A1 (es) | Uso de derivados de diamida antranilicos con sustituyentes heteroaromaticos y heterociclicos en combinacion con un agente de control biologico | |
| BR112013024957A2 (pt) | derviado de furanona ou um sal farmaceuticamente aceitável do mesmo | |
| ATE514698T1 (de) | Tetracyclische azapyrazinoindoline als 5-ht2- liganden | |
| BR112013007145A2 (pt) | composto ou sal farmacologicamente aceitável, medicamento, e, uso do composto ou sal farmacologicamente aceitável | |
| NI200700076A (es) | Derivados piridinicos de indolin-2-ona, su preparacion y su aplicacion en terapeutica | |
| CU20130037A7 (es) | Nuevos derivados dihidrobenzoxatiazepinas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |